Plandai Biotechnology Inc (OTCMKTS:PLPL) and Generex Biotechnology Corporation (OTCMKTS:GNBT) are the two OTC traded stocks that have been the center of attraction after they issued promising PRs. Plandai reported an amendment to its preciously finalized deal with USN Worldwide. Under the new amended deal with USN, it will now expand its Phytofare® sales to USN and associated contract manufacturer firms to the European Union.
Callum Cottrell-Duffield of Plandaí said that they are extremely delighted to expand contract with USN into the EU market. Clearly, it is a big opportunity for the company, as they believe the entry into the European market will increase Phytofare® catechin ingredient sales. As a pioneer in wellness and sports nutrition, USN knows the advantages of phyto-availability within existing product line-up.
The buzz
Coming to the announcement of Generex, the company updated its stockholders on the development progress of Generex Oral-lyn™. It issued a white paper highlighting the status of Generex Oral-lyn™ and presented at its annual meeting of stockholders. The white paper demonstrates the success of Generex’s initial attempts to enhance Generex Oral-lyn™ by increasing insulin concentrations. Generex Oral-lyn™ is the company’s patented buccal insulin spray product.
The white paper explains Generex’s leading efforts in the design and formulation of an alternative way for insulin delivery into the human body that will enable diabetic patients to avoid the inconvenience and discomfort of injections whilst enhancing and preserving the metabolic impact of the dosed insulin.
The focus
Highlighting the major biotech, Bernstein’s Vincent Chen and Geoffrey Porges stated that Gilead Sciences, Inc. (NASDAQ:GILD) and Amgen, Inc. (NASDAQ:AMGN) accounts for 71% of the total biotech market profit pool. However, it is only Gilead that is giving above-average return on capital. As of FY2014, Amgen and Gilead combined comprised for 71% of total industry profits, with Celgene Corporation (NASDAQ:CELG), Biogen Inc (NASDAQ:BIIB), Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) accounting for 10%, 12%, 5% and 3% of the total profit pool, respectively.
